Skip to content

Can the use of low dose radioactive seeds to guide surgical removal of small areas of abnormal breast tissue reduce the rate of second operation compared with standard hook-wire technique? (ROLLIS RCT: Radio-guided Occult Lesion Localisation using Iodine-125 Seeds)

Can Radio-guided Occult Lesion Localisation using Iodine-125 Seeds (ROLLIS) for excision of impalpable breast cancer reduce the rate of pathologically inadequate margins and/or subsequent oncological surgery compared with standard hook-wire localisation? A randomised controlled clinical trial.

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12613000655741
Acronym
ROLLIS RCT
Enrollment
659
Registered
2013-06-14
Start date
2013-09-17
Completion date
2018-03-23
Last updated
2020-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This study is comparing the use of low dose radioactive seeds to standard treatment for surgical removal guidance in breast cancer patients. Who is it for? You may be eligible to join this study, if you are a female aged 18 years or above and have been diagnosed with breast cancer that is non-palpable (i.e. the surgeon cannot feel it), and thus require a procedure known as localisation. Trial details: When an abnormal area in the breast needs to be removed after a needle biopsy (and the surgeon cannot feel it), the abnormal area is localised. We are comparing two different localisation techniques in this study. Participants will be randomly (by chance) assigned to one of two techniques. Participants in one group will undergo a procedure known as ROLLILS (radioguided occult lesion localisation and removal of impalpable breast cancers). This involves inserting a low-dose sterilised radioactive iodine seed into the patient's cancer under local anaesthesia with imaging guiding. The patient will then undergo breast conserving surgery within 4 days, during which the surgeon uses the seed to guide removal of the impalpable cancer. Participants in the other group will undergo the standard treatment, known as hook-wire guided localisation (HWL). This is when a hook-wire is placed in the breast on the day of breast conserving surgery by a radiologist. Participants are followed for up to 5 years post-surgery in order to evaluate clinical and cosmetic outcomes, disease recurrence and patient satisfaction. A cost benefit analysis will also be undertaken.

Interventions

The radiopharmaceutical product (medical device) is a needle with wax plug, containing a radioactive seed. I-125 seeds are entered on the Australian Register of Therapeutic Goods for a different purpose (prostate brachytherapy). Low activity seeds are packaged on-site into a sterile needle kit to be used for ROLLIS, under the Therapeutic Goods Administration Clinical Trials Notification scheme. Participants will give informed consent and be randomised to HWL or ROLLIS. For ROLLIS participant

The radiopharmaceutical product (medical device) is a needle with wax plug, containing a radioactive seed. I-125 seeds are entered on the Australian Register of Therapeutic Goods for a different purpose (prostate brachytherapy). Low activity seeds are packaged on-site into a sterile needle kit to be used for ROLLIS, under the Therapeutic Goods Administration Clinical Trials Notification scheme. Participants will give informed consent and be randomised to HWL or ROLLIS. For ROLLIS participants, a low-dose sterilised radioactive I-125 seed is placed within the patient’s cancer under local anaesthesia with imaging guidance. The approximate duration of the seed insertion procedure is 5 minutes. Localisation by seed may be up to 4 days prior to surgery. The standard 2-view mammogram will be obtained to confirm satisfactory positioning of the seed(s). The seed remains in situ until surgery. If the position of a seed is not ideal, a hook-wire will be inserted to guide the surgical excision. (A second seed may cause confusion rather than aid guidance, since the signal from each seed may not be distinct). In theatre, the surgeon then uses an intraoperative gamma probe to guide removal of the impalpable cancer containing the seed by breast conserving surgery (BCS) within 4 days.

Sponsors

Prof Christobel SAUNDERS
Lead SponsorIndividual

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

•Women 18 years or over. •Histologically confirmed invasive or in-situ carcinoma that is impalpable or poorly palpable (such that preoperative localisation is considered to be warranted by the treating surgeon), •Candidate for breast conserving surgery (BCS), based on clinical and radiological evaluation. Pleomorphic LCIS will be included as it is agreed to be of similar significance to Ductal carcinoma in situ (DCIS). •Completion of a signed and dated written informed consent obtained prior to participation.

Exclusion criteria

•Male breast cancer - mastectomy is treatment of choice. •Pregnancy - whilst the radiation dose involved in ROLLIS is very small, the ALARA principle (as low as reasonably achievable) mandates the exclusion. •Lactation - theoretical possibility of ductal migration of seed. •More than one separate malignant lesion in the same breast. •Non-pleomorphic lobular carcinoma in-situ (LCIS) - management remains controversial.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 16, 2026